Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants

Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants

Vaccines pave the way out of the SARS-CoV-2 pandemic. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Linda van Oosten, Jort J. Altenburg, Cyrielle Fougeroux, Corinne Geertsema, Fred van den End, Wendy A. C. Evers, Adrie H. Westphal, Simon Lindhoud, Willy van den Berg, Daan C. Swarts, Laurens Deurhof, Andreas Suhrbier, Thuy T. Le, Shessy Torres Morales, Sebenzile K. Myeni, Marjolein Kikkert, Adam F. Sander, Willem Adriaan de Jongh, Robert Dagil, Morten A. Nielsen, Ali Salanti, Max Søgaard, Timo M. P. Keijzer, Dolf Weijers, Michel H. M. Eppink, René H. Wijffels, Monique M. van Oers, Dirk E. Martens, Gorben P. Pijlman
Formato: article
Lenguaje:EN
Publicado: American Society for Microbiology 2021
Materias:
Microbiology
QR1-502
Acceso en línea:https://doaj.org/article/9d799f0e15554e7aafc11f877069c7c0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Vaccines pave the way out of the SARS-CoV-2 pandemic. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spike proteins: full-length S, stabilized secreted S, or the S1 domain. This two-component nanoparticle vaccine can now be further developed to help alleviate the burden of COVID-19.

Ejemplares similares